Member Info for gggg21

Polygon = aurora nominess and JP Morgan. It’s what this plan is and who is behind this all that will decide what is going on.

Anything the Synairgen board want voted on and passing they HAVE TO GO TO POLYGON first for approval as without their 25% nothing is going to be passed.

To pass any agm resolution any egm resolution. Any vote what so ever you need 75% plus of votes. Polygon owning 25% plus if they do this means they effectively say what goes. READ UP ON THE STOCK MARKET RULES

Given polygon average price being well over £1 I think there is value and hope here at current share price. But let’s see still hurting from Monday like most of us here.

No idea but without their say so no agm/egm etc would pass without their say so. Will find out what is going on in the next few days.

They have 22.56% . 2.44 more and they effectively control the company. Given that they were at this position close of play Monday and usually rns always a day after going over the threshold I bet they were buying still yesterday and today. I believe by end of week they will be controlling Synairgen. Nothing can be done without their say so at agm, no resolutions passed without them etc.

Theboyg you’ll be pleased to know all the futures are very blue this morning indicating opening up for the markets. Nasdaq futures currently 0.8% up. Dow 0.7% up. Should be a good day on the markets.

Reckon there will be intraday for this tomorrow given it’s been two weeks and volume continued. Friday volume was high and we know which mm was leading the charge again.

Saw it with Asos 450 instead of 4500 a while back, was cancelled shortly afterwards

Whole market deep red again as fears of russia/ukraine - does not matter about buys and sells, the markets has just pulled rug and pulled prices down. Wouldn't want news really at moment because of wider market, let the hysteria settle and then watch it shift back. 179 providing good support again, remember this was 179 the other week then shot over 200 a couple of days later. Low overall volume today

Argentina is one site for production ;)

Synairgen been very quiet on twitter all week, no tweet since 2nd Feb and not even updated their website with the new jobs yet.......

the whole market is deep red....

Tight as anything, was low volume yesterday but since last friday over 10m shares traded, polygon only needed just under 2m shares to go 19. So we maybe getting another tr1 later

And then this activ2 presentation Monday which is an NIH backed trial. It’s as if they are prepping/waving the flag before the day hmmmm https://www.eurekalert.org/news-releases/942698

https://twitter.com/nihdirector/status/1491887417535737860?s=21

In ~10% of cases, #SARSCoV2 infection triggers oxygen-deficient #COVID19 pneumonia. New #NIH-funded research suggests insufficient type 1 IFN immunity in the respiratory tract may account for viral spread, leading to pulmonary & systemic inflammation.

Do one ndn71, you wouldn’t speak to me like that in person. Sort yourself out I just think it’s a utter waste of a life you spending all day every day posting absolute drivel and commenting on every single post with utter drivel

Ndn71 - seriously are you ok, you at on this board all day yesterday until 1am in the morning and now first thing on your mind is to post on here first thing........this is not healthy at all do you do anything else but sit clicking refreshing, synairgen 24/7

Who knows but i can not see how synairgen does not get mentioned heavily monday therefore anything not in public domain will need an RNS. If no rns then very interesting as SABS has session......so this makes me wonder is something bigger going on.....looking forward to monday evening at the very least now.

Monday looks like the day POST-ACUTE SEQUELAE OF SARS-COV-2 IN NON-HOSPITALIZED ACTIV-2 TRIAL PARTICIPANTS (ACTG 5401/ACTIV-2; Poster Presentation: Monday, February 14 2022, 4:00 PM – 5:30 PM EST) Teresa H. Evering, et al.

ACTG 5401/ACTIV-2 is an ongoing phase 2/3 study evaluating the safety and efficacy of investigational treatments to treat non-hospitalized adults with mild to moderate COVID-19. This analysis reports on symptom diaries completed by participants.